Bexsero logo

médaille gravée par Albert de JAEGER, grand prix de Rome

Bexsero, winner of the UK Prix Galien 2014 for Innovative Product Award

UK flag This site is intended for UK health professionals only

Award-winning In October 2014 Bexsero was awarded the Innovative Product Award at the UK Prix Galien ceremony, recognising “20 years of pioneering research using an innovative approach to vaccine development”

A dangerous killer Meningococcal disease can lead to death within 24-48 hours of the first symptoms, leaving a very narrow window for diagnosis and intervention

Life-long impact Among survivors of meningococcal disease,
10%-20% will be left with permanent disabilities

Introducing Bexsero® In March 2014, Bexsero was recommended by the JCVI for introduction into the childhood immunisation schedule for infants starting at 2 months of age. Find out more here.

Links

1. JCVI position statement on use of Bexsero® meningococcal B vaccines in the UK. Available at https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf Last accessed October 2014

This is an external link, which will open in a new window. Novartis Vaccines and Diagnostics Limited is not responsible for the content of this external site.

Continue

2. Department of Health, Press release, 21st March 2014, https://www.gov.uk/government/news/meningococcal-b-vaccination-programme-to-be-introduced Last Accessed October 2014

This is an external link, which will open in a new window. Novartis Vaccines and Diagnostics Limited is not responsible for the content of this external site.

Continue

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/
Adverse events should also be reported to Novartis Vaccines and Diagnostics Limited at https://psi.novartis.com/